CLINICAL GENETIC TESTING FOR CANCER SUSCEPTIBILITY πŸŽ—️

“β„‚π•’π•Ÿπ•”π•–π•£ π•šπ•€ 𝕒 π•˜π•–π•Ÿπ•–π•₯π•šπ•” π••π•šπ•€π•–π•’π•€π•– 𝕒π•₯ π•šπ•₯𝕀 𝕔𝕠𝕣𝕖. π•Œπ•Ÿπ••π•–π•£π•€π•₯π•’π•Ÿπ••π•šπ•Ÿπ•˜ π•šπ•Ÿπ•™π•–π•£π•šπ•₯𝕖𝕕 π•‘π•£π•–π••π•šπ•€π•‘π• π•€π•šπ•₯π•šπ• π•Ÿ π• π•‘π•–π•Ÿπ•€ π•₯𝕙𝕖 𝕕𝕠𝕠𝕣 π•₯𝕠 π•šπ•Ÿπ•₯𝕖𝕣𝕔𝕖𝕑π•₯π•šπ•Ÿπ•˜ π•”π•’π•Ÿπ•”π•–π•£ 𝕓𝕖𝕗𝕠𝕣𝕖 π•šπ•₯ π•“π•–π•˜π•šπ•Ÿπ•€.” - Prof. Bert Vogelstein

🧬 Advances in clinical genetic testing transformed cancer prevention and treatment by revealing inherited mutations that heighten susceptibility to specific cancers. Roughly 5-10% of all cancers are hereditary, often linked to mutations in genes such as BRCA1/2 (breast and ovarian cancers) and MLH1, MSH2, MSH6, and PMS2 in Lynch syndrome (colorectal and endometrial cancers). Identifying these variants enables early detection, preventive measures, and precision therapy prepared to individual genetic profiles.

           πŸ”Ή Testing begins with genetic counseling, followed by targeted or multi-gene sequencing using next-generation technologies; now faster and more cost-effective than ever. Yet, interpretation requires expert insight, as not all variants translate to clinical risk.

          πŸ”Ή Despite its promise, ethical and psychosocial concerns persist. Questions of privacy, data sharing, and potential discrimination remain relevant, even with legal safeguards such as GINA. Emotional consequences of learning one’s genetic risk further highlight the need for robust counseling frameworks.

          πŸ”Ή The future lies in integrating compute variant interpretation, equitable global access, and gene-editing tools like CRISPR for preventive innovation.

          ➡️ As families become more aware of their hereditary risks, society must strive to provide the support and resources necessary to navigate the complexities of genetic information, ensuring that clinical genetic testing serves as a tool for improved health rather than a source of anxiety. With careful consideration and a commitment to ethical practices, clinical genetic testing has the potential to reshape the future of cancer care and prevention.

⚠️ In an Oystershell, clinical genetic testing for cancer susceptibility represents a blueprint in modern medicine, offering unprecedented opportunities for early detection, prevention, and precise treatment. While the potential benefits are significant, they must be balanced with ethical considerations surrounding privacy, discrimination, and psychological impacts.

Abubakar Abubakar ✍🏼

• Kuchenbaecker, K. B. et al. JAMA (2017); 317(23):2402-2416.

• Lynch, H. T. & de la Chapelle, A. New England Journal of Medicine (2003); 348:919-932.

• Rehm, H. L. et al. Nature Reviews Genetics (2021); 22(7):467-484.

• Vears, D. F. & Niemiec, E. Nature Reviews Genetics (2023); 24:327-341.

• Rahman, N. New England Journal of Medicine (2014); 371:2239-2251.

#ClinicalGenetics #CancerGenomics #GeneticCounseling #GeneticTesting #PrecisionOncology #HereditaryCancer #GenomicMedicine #Bioethics #CRISPR #CancerResearch #PublicHealth⚕️

Popular posts from this blog

GENE DUPLICATIONS IN EVOLUTIONARY INNOVATION

Image
"π”Ύπ•–π•Ÿπ•– π••π•¦π•‘π•π•šπ•”π•’π•₯π•šπ• π•Ÿ π•‘π•£π• π•§π•šπ••π•–π•€ 𝕒 π•£π•–π••π•¦π•Ÿπ••π•’π•Ÿπ•”π•ͺ π•₯𝕙𝕒π•₯ 𝕗𝕣𝕖𝕖𝕀 π• π•Ÿπ•– 𝕔𝕠𝕑π•ͺ π•—π•£π• π•ž 𝕀𝕖𝕝𝕖𝕔π•₯π•šπ•§π•– π•”π• π•Ÿπ•€π•₯π•£π•’π•šπ•Ÿπ•₯, π•’π•π•π• π•¨π•šπ•Ÿπ•˜ π•šπ•₯ π•₯𝕠 𝕖𝕩𝕑𝕝𝕠𝕣𝕖 π•Ÿπ•–π•¨ π•—π•¦π•Ÿπ•”π•₯π•šπ• π•Ÿπ•’π• 𝕀𝕑𝕒𝕔𝕖." - Dr. Richard Lewontin 🧬 Gene duplications are a driving force in evolution, offering raw material for innovation. They arise through mechanisms like unequal crossing over, retroposition, or whole-genome duplication (WGD). Once a gene is duplicated, one copy can conserve its original role, while the other diverges; fueling new functions, adaptations, or even nonfunctionalization (pseudogenes).           πŸ”Ή The evolutionary fates of gene duplications includes: Subfunctionalization: split ancestral functions across duplicates. Neofunctionalization: gain of new roles, which is vital for innovation. Pseudogenization: loss of function. A classic case is the globin gene family: duplications enabled the evolution of h...
Read more

MUTATIONAL SIGNATURES IN CANCER GENOMES πŸŽ—️

Image
“𝕋𝕙𝕖 π•˜π•–π•Ÿπ• π•žπ•– 𝕠𝕗 𝕖𝕧𝕖𝕣π•ͺ π•”π•’π•Ÿπ•”π•–π•£ π•‘π•£π• π•§π•šπ••π•–π•€ 𝕒 π•œπ•šπ•Ÿπ•• 𝕠𝕗 ‘π•’π•£π•”π•™π•’π•–π• π•π• π•˜π•šπ•”π•’π• 𝕣𝕖𝕔𝕠𝕣𝕕,’ π•¨π•£π•šπ•₯π•₯π•–π•Ÿ π•šπ•Ÿ π•₯𝕙𝕖 𝔻ℕ𝔸 𝕔𝕠𝕕𝕖 π•šπ•₯𝕀𝕖𝕝𝕗, 𝕠𝕗 π•₯𝕙𝕖 𝕖𝕩𝕑𝕠𝕀𝕦𝕣𝕖𝕀 π•₯𝕙𝕒π•₯ 𝕔𝕒𝕦𝕀𝕖𝕕 π•₯𝕙𝕖 π•žπ•¦π•₯𝕒π•₯π•šπ• π•Ÿπ•€ π•₯𝕙𝕒π•₯ 𝕝𝕖𝕒𝕕 π•₯𝕠 π•₯𝕙𝕖 π•”π•’π•Ÿπ•”π•–π•£.” - Sir. Mike Stratton 🧬 Cancer arises from the accumulation of somatic mutations, each carrying clues about the biological and environmental forces that shaped the tumor’s evolution. With the advent of high-throughput sequencing and large-scale projects like TCGA and ICGC, we have uncovered distinct mutational signatures; recurring patterns of DNA alterations that reflect specific mutagenic processes. πŸ”Ή What are mutational signatures? They are characteristic patterns of nucleotide substitutions, insertions, or deletions, shaped by mechanisms such as aging, tobacco exposure, UV light, or defective DNA repair. For example, Signature 1 correlates with age-related deamin...
Read more